About
Regenxbio Inc (NASDAQ:RGNX) — investor relations, events, news, and company updates on 6ix.
Latest News
Mar 11 2026
REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
Mar 5 2026
REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Mar 4 2026
REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Feb 25 2026
REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Feb 9 2026
REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II
Financials
Revenue
$170.44 M
Market Cap
$440.26 M
EPS
-3.76
Translate